Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study
Arifin SMN, Zimmer C, Trotter C, Colombini A, Sidikou F, LaForce FM, Cohen T, Yaesoubi R. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study. Medical Decision Making 2019, 39: 553-567. PMID: 31268405, PMCID: PMC6786941, DOI: 10.1177/0272989x19859899.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisEpidemicsHumansMass VaccinationMeningitis, MeningococcalMeningococcal VaccinesModels, StatisticalNeisseria meningitidisNigerVaccines, ConjugateConceptsReactive campaignsSerogroup replacementConjugate vaccineOne-time catchPolyvalent meningococcal vaccineRoutine infant vaccinationMeningococcal conjugate vaccineMeningococcal polysaccharide vaccineRoutine infant immunizationCurrent vaccination practicesImportant health benefitsCost-effectiveness thresholdStandard cost-effectiveness thresholdsAgent-based transmission modelVaccination seriesImmunization seriesInfant vaccinationInfant immunizationPolysaccharide vaccineMeningococcal vaccineVaccination practicesPolyvalent vaccineLaboratory confirmationMenAfriVacSerogroups A